Dacuronium bromide
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 581187

CAS#: 27115-86-2

Description: Dacuronium bromide is an aminosteroid neuromuscular blocking agent Pancuronium (P178500) with much weaker activity which was never marketed. It acts as a competitive antagonist of the nicotinic acetylcholine receptor (nAChR).

Chemical Structure

img
Dacuronium bromide
CAS# 27115-86-2
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 581187
Name: Dacuronium bromide
CAS#: 27115-86-2
Chemical Formula: C33H58Br2N2O3
Exact Mass: 688.28
Molecular Weight: 690.650
Elemental Analysis: C, 57.39; H, 8.47; Br, 23.14; N, 4.06; O, 6.95

Price and Availability

Size Price Availability Quantity
10mg USD 330
100mg USD 1690
Bulk inquiry

Synonym: Dacuronium bromide; Dacuronii bromidum; EINECS 248-233-9; NB 68; NB68; ORG 6368;

IUPAC/Chemical Name: 2-beta, 16-beta-Dipiperidino-5-alpha-androstan-3-alpha,17-beta-diol 3-acetate dimethobromide

InChi Key: DCMGIRFMSWIIHH-LKRYSLHCSA-N

InChi Code: DCMGIRFMSWIIHH-LKRYSLHCSA-N

SMILES Code: C[C@@]12[C@@H](O)[C@@H](N3CCCCC3)C[C@@]1([H])[C@]4([H])CC[C@@]5([H])C[C@H](OC(C)=O)[C@@H](N6CCCCC6)C[C@]5(C)[C@@]4([H])CC2.CBr.CBr

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Product Data
Instruction:
View handling instruction
Biological target: Dacuronium bromide acts as a competitive antagonist of the nicotinic acetylcholine receptor (nAChR).
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 690.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Feldman SA, Tyrrell MF. A new steroid muscle relaxant. Dacuronium-NB.68 (Organon). Anaesthesia. 1970 Jul;25(3):349-55. doi: 10.1111/j.1365-2044.1970.tb00220.x. PMID: 4246972.


2: Norman J, Katz RL. Some effects of the steroidal muscle relaxant, dacuronium bromide, in anaesthetized patients. Br J Anaesth. 1971 Apr;43(4):313-9. doi: 10.1093/bja/43.4.313. PMID: 4252525.


3: Baden JM. Anticholinergic actions of steroid muscle relaxants. Anaesthesia. 1976 Mar;31(2):215-8. doi: 10.1111/j.1365-2044.1976.tb11794.x. PMID: 937668.


4: Agoston S, Crul EJ, Kersten UW, Houwertjes MC, Scaf AH. The relationship between disposition and duration of action of congeneric series of steroidal neuromuscular blocking agents. Acta Anaesthesiol Scand. 1977;21(1):24-30. doi: 10.1111/j.1399-6576.1977.tb01188.x. PMID: 842267.


5: Fotherby K. Clinical experience and pharmacological effects of an oral contraceptive containing 20 micrograms oestrogen. Contraception. 1992 Nov;46(5):477-88. doi: 10.1016/0010-7824(92)90151-i. PMID: 1458894.


6: Mercilon--a new low-dose combined oral contraceptive. Drug Ther Bull. 1989 Jun 26;27(13):51-2. Erratum in: Drug Ther Bull 1989 Oct 2;27(20):80. PMID: 2535273.


7: Booij LH, Vree TB, Crul JE. Org-NC45: a new steroidal non-depolarizing muscle relaxant. Pharm Weekbl Sci. 1982 Feb 19;4(1):1-4. doi: 10.1007/BF02112349. PMID: 6122196.


8: Streuli I, Fraisse T, Pillet C, Ibecheole V, Bischof P, de Ziegler D. Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril. 2008 Aug;90(2):395-400. doi: 10.1016/j.fertnstert.2007.06.023. Epub 2007 Oct 24. PMID: 17919608.


9: Song S, Chen JK, Yang PJ, He ML, Li LM, Fan BC, Rekers H, Fotherby K. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel. Contraception. 1992 Jun;45(6):523-32. doi: 10.1016/0010-7824(92)90103-z. PMID: 1535580.


10: Koo YA, Lee B, Park HJ, Choi J, Lee E, Choi D. Altered vascular endothelial growth factor expression during GnRH antagonist protocol in women of reproductive age with normal baseline hormone profiles. Fertil Steril. 2009 Mar;91(3):744-8. doi: 10.1016/j.fertnstert.2007.12.068. Epub 2008 Mar 5. PMID: 18321491.


11: Minnema MC, Janssen HL, Niermeijer P, de Man RA. Budd-Chiari syndrome: combination of genetic defects and the use of oral contraceptives leading to hypercoagulability. J Hepatol. 2000 Sep;33(3):509-12. doi: 10.1016/s0168-8278(00)80290-1. PMID: 11020010.


12: Basdevant A, Conard J, Pelissier C, Guyene TT, Lapousterle C, Mayer M, Guy- Grand B, Degrelle H. Hemostatic and metabolic effects of lowering the ethinyl- estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel. Contraception. 1993 Sep;48(3):193-204. doi: 10.1016/0010-7824(93)90141-s. PMID: 8222650.


13: Coenen CM, Thomas CM, Borm GF, Hollanders JM, Rolland R. Changes in androgens during treatment with four low-dose contraceptives. Contraception. 1996 Mar;53(3):171-6. doi: 10.1016/0010-7824(96)00006-6. PMID: 8689882.


14: Rechberger T, Baranowski W, Bogusiewicz M, Postawski K, Jakimiuk AJ, Tomaszewski J, Kulik-Rechberger B, Jakowicki JA. Serum concentrations of markers of type I collagen metabolism in women taking monophasic oral contraceptives. Ginekol Pol. 2002 Feb;73(2):81-6. PMID: 12001776.


15: Uchikova E, Malinova M, Pekhlivanov B, Ledzhev I. Khemostazen profil pri zheni upotrebiavashti niskodoziraniia oralen kontratseptiv--Mercilon (predvaritelno sŭobshtenie) [Hemostatic profile of women using low-dose oral contraceptive Mercilon. (Preliminary report)]. Akush Ginekol (Sofiia). 2002;41(3):23-5. Bulgarian. PMID: 12145973.


16: Akerlund M, Røde A, Westergaard J. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol. Br J Obstet Gynaecol. 1993 Sep;100(9):832-8. doi: 10.1111/j.1471-0528.1993.tb14309.x. PMID: 8218004.


17: Kirkman RJ, Pedersen JH, Fioretti P, Roberts HE. Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age. Contraception. 1994 Jan;49(1):33-46. doi: 10.1016/0010-7824(94)90107-4. PMID: 8137624.


18: Djurica S, Cirović M, Lukić B, Gregorić G, Tasovac-Ponomarev D. Some extrathyroid regulatory mechanisms' aspects in thyroid humoral state at the delivery. Mater Med Pol. 1990 Jul-Sep;22(3):198-201. PMID: 2132426.


19: Lukić B, Barjaktarović N. Sister-chromatid exchanges in newborns after normal and progesterone-treated pregnancies. Mutat Res. 1987 Jun;191(2):121-4. doi: 10.1016/0165-7992(87)90140-0. PMID: 3600694.